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Background: Proper administration of the human papillomavirus (HPV) vaccine (three doses at 0, 2, and 6 months)
will likely influence the vaccine’s effectiveness and the impact of vaccination programs on health outcomes.
Therefore, we assessed HPV vaccine series completion and on-time dosing in Canada’s largest publicly funded,
school-based HPV vaccination program.
Methods: Using administrative health and immunization databases, we identified a population-based cohort of girls
eligible for Ontario’s Grade 8 HPV vaccination program in the 2007/08-2009/10 program years who received at least
one dose of the vaccine. We determined the number of doses received and calculated the percentage of girls that
completed the three-dose series in Grade 8 and Grades 8–9. To assess on-time dosing, the number of days between
doses 1–2, 2–3, and 1–3 was calculated and categorized (e.g., too short, on schedule, too long) based on the
manufacturer’s recommendations. Analyses were also stratified by program year.
Results: We identified a cohort of 55,798 girls who initiated the vaccination series. Series completion was high in
the Grade 8 window (81.8%) and increased by approximately 6% in Grade 9. Series completion was similar across the
three program years. 70.8%, 98.5%, and 86.1% of girls were classified as ‘on schedule’ for dosing intervals 1–2, 2–3, and
1–3, respectively; 70.0% of girls received all three doses in perfect accordance with dosing recommendations. Stratification
revealed that on-time dosing was highest in the first two years of the program (85.6% and 80.6%), but dropped to 42.1%
in the 2009/10 year when H1N1 vaccination programs were prioritized.
Conclusions: Our study demonstrates that delivery of the HPV vaccine through a free, school-based program is
an effective method of ensuring high completion and on-time dosing, but may not be sufficient to guarantee
high coverage.
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Gardasil® is a quadrivalent human papillomavirus (qHPV)
vaccine designed to protect against infection with four
types of HPV that cause 90% of anogenital warts (HPV-6
and −11) and 70% of cervical cancers (HPV-16 and −18)
[1-3]. The largest randomized controlled trial (RCT) of* Correspondence: linda.levesque@queensu.ca
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unless otherwise stated.the qHPV vaccine showed it to be highly efficacious in
preventing vaccine-type-specific anogenital warts (99%;
95% CI 96-100%) and pre-cancerous cervical lesions
(96%; 95% CI 91-98%) [4]; other RCTs reported similar
levels of efficacy [5,6]. Importantly, these promising
results were established following adherence and com-
pliance to the recommended three-dose vaccine schedule
of 0, 2 and 6 months. Although the qHPV vaccine has
now been commercially available for over six years, there
is limited information on whether individuals outside
of clinical trials have been following the recommended. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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will likely influence the vaccine’s effectiveness and the
impact of vaccination programs on adolescent health out-
comes, we undertook a population-based retrospective
cohort study to evaluate HPV vaccine series comple-
tion (adherence) and on-time dosing (compliance) among
Grade 8 girls in a publicly funded, school-based HPV
vaccination program in Ontario, Canada.
Methods
Ontario’s Grade 8 HPV vaccination program
Soon after the qHPV vaccine was licensed for use in
Canada, the National Advisory Committee on Immu-
nization (NACI) released a statement recommending
routine immunization for all girls aged 9–13 years [7].
Based on these recommendations, the Canadian govern-
ment announced in 2007 that they would be investing
$300 million toward the launch of a national qHPV vac-
cination program aimed at immunizing young girls,
ideally before the onset of sexual activity. Since this
money was allocated to provinces and territories on a
per-capita basis, the Ontario government received $117
million to design and implement Ontario’s Grade 8 HPV
vaccination program [8]. This program, which began in
September of 2007, offers three doses of the qHPV vac-
cine free of charge to all Grade 8 girls in the province.
The program is coordinated by the province’s 36 health
units (i.e., administrative health regions), primarily
through school-based immunization clinics. As a result,
doses are generally administered by public health nurses
in schools in September/October, November/December,
and March/April of each school year to correspond with
the recommended 0-, 2-, 6-month dosing schedule of
the vaccine. While the vast majority of publicly funded
HPV vaccine doses are administered through the school
clinics, eligible girls also have the option of obtaining the
vaccine at their health unit or through their family
physician at no cost. Girls have until the end of their
Grade 8 year to initiate the vaccination series (Grade 8
eligibility period) and until the end of their Grade 9 year
to complete it (program eligibility period). Approximately
84,000 girls are eligible for Ontario’s Grade 8 HPV
vaccination program each year, but HPV vaccination is
optional [9].
Data sources
Two administrative health databases were used for this
study – the Registered Persons Database (RPDB) and the
Immunization Record Information System (IRIS) data-
base. The RPDB is the population registry of insured
persons for Ontario’s universal healthcare programs. It has
been used extensively in health research, including in the
post-marketing evaluation of drugs and vaccines [10-12].
In this study, the RPDB was used for information on thesocio-demographics of cohort members. A copy of the
RPDB is housed at the Institute for Clinical Evaluative
Sciences (ICES).
Information on mandatory and optional vaccinations,
including qHPV vaccination, was obtained using the
Immunization Record Information System (IRIS) database.
Developed by the Ministry of Health and Long-Term
Care, IRIS databases are maintained by each of Ontario’s
36 health units to track and record the vaccinations of all
school-aged children in their jurisdiction. As a result, the
province’s 36 IRIS databases contain individual-level infor-
mation on all qHPV vaccine doses administered through
the publicly funded program, regardless of whether the
vaccine is administered at school, a physician’s office, or
the public health unit. Although IRIS may not capture all
HPV vaccine doses of eligible girls who chose to receive
the vaccine outside of the publicly funded program, given
the high cost of the otherwise free vaccine (approximately
$450CAD for three doses), this is unlikely to have an
important impact on the completeness of the IRIS data.
To investigate the validity of the HPV vaccine data con-
tained in IRIS, a validation study was executed in one of
Ontario’s health units (Kingston, Frontenac, Lennox, and
Addington; KFLA) using paper vaccination records as the
gold standard. The validation study demonstrated that the
database captured individuals’ HPV vaccination status
with high sensitivity (99.8%; 95% CI: 99.3-99.9) and speci-
ficity (97.7%; 95% CI: 96.3-98.7); it also demonstrated that
98.6% of vaccination dates were accurate [13]. At the time
of the current study an encrypted copy of the IRIS data-
base of 21 health units had been transferred to ICES and
were available for use in this study. In the IRIS and RPDB
databases housed at ICES, residents of Ontario are repre-
sented by a unique encrypted identifier, enabling complete
record linkage at the level of the individual across data-
bases and time. In Ontario, the transfer, linkage, and
encryption of health data is permitted under section 45.1
of the Personal Health Information Protection Act (2004)
and was executed under data sharing agreements between
each participating health unit and ICES. Although all 36
health units were recruited for this study at the same time,
due to various administrative delays, the data for the
remaining 15 health units were not yet available.
Study population
The source population for this study was the Ontario
Grade 8 HPV Vaccine Cohort, which is comprised of all
girls eligible for the province’s publicly funded HPV vac-
cination program between 2007 and 2011. Members of
the source cohort were identified using the RPDB and
IRIS databases. Since school grade is not available in these
databases, the cohort was identified using birth year be-
cause girls are typically 13 years of age by December 31 of
their Grade 8 year. Therefore, the source cohort consisted
Lim et al. BMC Public Health 2014, 14:1029 Page 3 of 9
http://www.biomedcentral.com/1471-2458/14/1029of all girls born in 1994, 1995, 1996, and 1997 in Grade 8
in Ontario in the 2007/08, 2008/09, 2009/10, and 2010/11
school years, respectively. Although this method of cohort
identification may miss girls who were advanced or held
back a school grade, the validation study on the KFL&A
IRIS database demonstrated that this cohort definition
correctly identified 96.4% of eligible girls [14]. Cohort
members were followed from September 1 of their Grade
8 year (cohort entry) until the first of: date of death or
date of study end (March 31, 2011). For the purposes of
the current study, the source cohort was restricted to girls
for whom complete IRIS data were available. As a result,
the study cohort included girls who resided within 21 of
the participating health units during 2007/08-2009/10
program years (i.e., 1994–1996 birth cohorts); the 1997
birth cohort was excluded because girls had not com-
pleted their Grade 8 year by the study end date. Subse-
quently, IRIS was used to further restrict the cohort to
girls who received at least one dose of the qHPV vaccine
during study follow up. Girls who received a dose prior to
cohort entry were excluded. After record linking the study
cohort with the IRIS database, we discovered that a small
number of cohort members had duplicate qHPV vacci-
nation records with discordant vaccination dates (n = 9).
Most often, such duplicate records arise when a girl
moves from one health unit to another and the parental
self-report of vaccination status does not correspond with
the electronic record. These girls were excluded from the
study cohort because the correct vaccination date could
not be readily identified.
HPV vaccination status and dose timing
Information on the qHPV vaccination history (e.g., date
of administration) of cohort members was ascertained
using the IRIS database. To describe HPV vaccine doses,
the number of doses received by each cohort member
was determined. To assess vaccine series completion
(adherence), cohort members were categorized based on
whether or not they received the three recommended
doses of the vaccine (1–2 doses vs. ≥3 doses) in the
Grade 8 eligibility period (i.e., September 1 until August
31 of the girl’s Grade 8 year) and in the program eligibility
period (i.e., September 1 of Grade 8 until August 31 of
Grade 9); in accordance with the program guidelines, girls
had to have initiated the vaccination series in Grade 8 in
order to be classified as adherers. To assess on-time dos-
ing (compliance) with the recommended 0-, 2-, 6-month
schedule, the number of days between doses (1–2, 2–3,
1–3) was calculated. Each dosing interval was sub-
sequently classified according to how it corresponded with
the recommended dosing interval (e.g., too short, on
schedule, too long). These classifications were created
based on the dosing schedule (and ‘flexibility period’) spe-
cified in the Gardasil® product monograph [1]. Specifically,the interval between dose one and two was categorized as:
(i) too short (<30 days), (ii) on schedule (30–90 days), or
(iii) too long (>90 days); the interval between dose two
and three was dichotomized based on whether it met the
minimum recommended interval of at least three months
(<90 days vs. ≥90 days); and the interval between dose one
and three (time to series completion) was classified as: (i)
too short (interval one to three <120 days or interval two
to three <90 days), (ii) on schedule (interval one to three
120–240 days and interval two to three ≥90 days), (iii)
acceptable (interval one to three 241–365 days), or (iv)
too long (interval one to three >365 days). The ‘acceptable’
category was created to address the fact that the product
monograph stipulates that all three doses should be given
within a one-year period and that the third dose should be
given by Month 8 (Day 240). Finally, on-time dosing was
dichotomized based on whether girls received all three
doses according to the recommendations (i.e., all intervals
‘on schedule’). On-time dosing was calculated overall as
well as by program year.
Baseline characteristics
The RPDB and IRIS databases were used to ascertain
baseline information on the socio-demographics and
vaccination history of cohort members.
The socio-demographic factors considered included
age, place of residence, and neighbourhood income quin-
tile at cohort entry. Place of residence and neighbourhood
income were obtained by linking a girl’s postal code at
cohort entry with the 2006 Canadian Census data. Neigh-
bourhood incomes were categorized into provincial quin-
tiles, and place of residence was dichotomized as urban
(≥10,000 persons) or rural (<10,000 persons) [15].
IRIS was used to ascertain information on vaccines
received prior to cohort entry. In particular, IRIS was used to
determine whether cohort members had received the
measles-mumps-rubella (MMR) and diphtheria-tetanus-polio
(DTP) vaccines (which are considered mandatory under the
Immunization of School Pupils Act, 1982 [16]), as well as the
hepatitis B and meningococcal conjugate vaccines (which are
optional vaccines offered to all Grade 7 students in Ontario
through school-based immunization clinics). Previous vaccin-
ation was defined based on receipt of at least one dose of the
vaccine of interest anytime prior to cohort entry.
Statistical analysis
Means and proportions of continuous and categorical
variables were calculated to describe the baseline charac-
teristics of the study cohort.
To describe qHPV vaccine use, the proportion of cohort
members who received one, two, three, or greater than
three doses was calculated. To determine vaccine series
completion, we calculated the proportion of cohort mem-
bers who completed the vaccination program in the Grade
8 eligibility period and the proportion of cohort members
who completed the vaccination series during the program
eligibility period. These analyses were performed overall as
well as by program year.
To assess dose intervals, we determined the number of
days between Dose 1 and Dose 2 (among girls who received
at least two doses), Dose 2 and Dose 3, and Dose 1 and Dose
3 (among girls who received at least three doses). Univariate
statistics were used to describe these intervals. As previously
described, dose timing was categorized on the basis of
compliance with the recommended vaccine schedule; pro-
portions were used to describe these measures of compliance.
P-values were calculated to assess significant changes in
use across program year and eligibility period. Chi-square
tests were used when observations were independent
(i.e., across program year) and McNemar’s tests were
used when observations were not independent (i.e.,
across eligibility period).
All statistical analyses were performed using Statistical
Analysis Software (SAS) version 9.2 (SAS Institute Inc.,
Cary, NC).
Ethics
This study was approved by Queen’s University’s Health
Sciences Research Ethics Board and Sunnybrook Health
Sciences Centre’s Ethics Review Board.
Results
Within the 21 health units for which data were available,
111,798 girls were eligible for publicly funded HPV vaccin-
ation in the 2007/09 to 2009/10 school years. These girls
represented approximately 40% of all girls eligible for pub-
licly funded qHPV vaccination in Ontario; geographically,
they were representative of all girls eligible for publicly
funded qHPV vaccination in Ontario (Figure 1). Approxi-
mately 50% (N = 55,798) of girls within our study sample
initiated the HPV vaccination series during the study period
and comprised our study cohort. Cohort members were a
mean age of 13.2 years at cohort entry and were followed
for an average of 2.6 years (Table 1). Most cohort members
(84.5%) resided in an urban setting and approximately one
third resided in lower-income neighborhoods. Almost all
cohort members had received the MMR and DTP vaccines,
and most had received the optional hepatitis B and menin-
gococcal conjugate vaccines; 73.8% had received all four
vaccines.
Figure 2 depicts the number of HPV vaccine doses
received by cohort members during their Grade 8 and 9
school years. While the number of doses received in the
2009/10 year was statistically significantly different than
those in the previous program year, the absolute differ-
ences were small. Only 0.15% of girls received more than
the recommended three doses.
Figure 1 Geographic representation of participating health units. The green regions represent health units whose immunization records
were available at the time of the analysis
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Table 1 Baseline characteristics of study cohort (N = 55,798)
Characteristic n (%)
Socio-demographics










5 (high) 11,698 (21.0)
Missing 203 (0.4)
Vaccination History
Mandatory Vaccines 55,094 (98.7)
Measles, mumps, rubella (MMR) 55,272 (99.1)
Diphtheria, tetanus, pertussis (DTP) 55,316 (99.1)
Optional Vaccines 41,505 (74.4)
Hepatitis B 48,393 (86.7)
Meningococcal conjugate 44,181 (79.2)
Mandatory and optional vaccines 41,158 (73.8)
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bility period (81.8%) and increased by approximately 6%
in Grade 9 (Figure 3). Few cohort members (n = 136) ini-
tiated the vaccination series after the program eligibility
period (data not shown).
On average, the time between doses one and two, two
and three, and one and three was 2.8 months (standard
deviation [SD] = 1.5), 4.2 months (SD = 1.6), and 6.9 months
(SD = 2.0), respectively. Figure 4 describes compliance
with the recommended dosing intervals. Time to series
completion (Dose 1–3) was good, with 86.1% girlsFigure 2 Number of doses received during the program eligibility pe
from previous program year (p<0.05).receiving their third dose in perfect accordance with the
recommendation and an additional 9.9% completing
their series within one year. A small percentage of doses
were received earlier than recommended (<2.0%). Although
only 70.8% of girls received their second dose within the
recommended time frame, Table 2 (which stratifies com-
pliance by program year) demonstrates that on-time re-
ceipt was high in the first two program years, but dropped
to 43.5% in 2009/10. In accordance with this drop in Year
3, overall, only 70.0% received all doses of the vaccine on
schedule, despite on-time dosing of 86% and 81% in the
first two years.
Discussion
Using population-based data from Canada’s most populous
province, Ontario, we found that completion of the HPV
vaccine’s three-dose series through a publicly funded, school-
based program was high. Moreover, it was consistently high
across the first three years that the program was offered.
Generally, compliance with the recommended timing of the
dosing schedule was also good, but there were delays in the
administration of Dose 2 in the 2009/10 program year.
Almost 90% of cohort members who initiated the
HPV vaccination series went on to receive all three rec-
ommended doses of the vaccine. Not only is this number
impressive in its own right, but it also represents one of
the highest levels of series completion that has been
reported to date [17-23]. Moreover, if, as suggested by
recent studies [24,25], two doses of the HPV vaccine pro-
vide as much protection as the full series, then over 95%
of our study population would be considered fully immu-
nized. Within this group, a small percentage is documented
as having received more than three doses of the vaccine.
While some of these cases may be the result of documenta-
tion errors or erroneous self-reports, excess vaccination has
been previously reported in situations where multiple
doses are involved [26]; therefore, the clinical impact
of such potential medical errors must be investigated.riod, stratified by program year. *Proportion significantly different
Figure 3 Completion of the three-dose series across program year, according to eligibility period. *Proportion in program eligibility
period (i.e., Grade 8-9) significantly different from proportion in Grade 8 eligibility period (p<0.0001).
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completion and on-time dosing of quadrivalent HPV vac-
cine within the context of a publicly funded, school-based
program. However, there have been some reports on
compliance when the vaccine is accessed through private
means. For example, Tan et al. [27] reported on series
completion and on-time dosing of qHPV vaccine doses
in North Carolina. They found that, among the 138,823
females who initiated the vaccination series, only 55%
completed the series and 28% completed it on time. Fur-
thermore, they found that both completion and on-time
dosing decreased dramatically between 2006 and 2009.
Similarly, Dorell et al. [28] reported on compliance with












































Figure 4 Compliance with recommended dosing intervals.a nationally representative sample of girls aged 13–17
years in the United States. They found that almost half
of girls who completed the vaccination series did so in a
period longer than the recommended interval. In con-
trast, our findings showed that 70% of girls completed
each aspect of the dosing regimen in perfect accordance
with the recommended dose-timing schedule. We also
found that usage was fairly consistent across program
years. The fact that series completion and on-time dos-
ing were so much greater in our study population likely
reflects the value of a well-run publicly funded program
delivered through school-based clinics, where a student
need only be present at school to receive her next
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Table 2 Compliance by program year
Compliance (%)
Program year(s) p-value*
2007/08 2008/09 2009/10 2007/08 - 2009/10 2007/08 & 2008/09 2008/09 & 2009/10
Dose 1-2
Short 0.2 0.2 1.0 0.5
<0.0001 <0.0001On schedule 85.7 82.1 43.5 70.8
Long 14.2 17.6 55.4 20.8
Dose 2-3
Short 1.2 0.5 3.2 1.6
<0.0001 <0.0001
On schedule 98.8 99.5 96.8 98.4
Dose 1-3
Short 1.2 0.5 3.9 1.8
<0.0001 <0.0001
On schedule 89.8 89.0 79.1 86.1
Acceptable 7.4 7.2 15.4 9.9
Long 1.7 3.4 1.6 2.3
Overall
All on schedule 85.6 80.6 42.1 70.0
<0.0001 <0.0001Not on schedule 14.4 19.4 57.9 30.0
*based on Chi-square tests.
Lim et al. BMC Public Health 2014, 14:1029 Page 7 of 9
http://www.biomedcentral.com/1471-2458/14/1029vaccine use was not perfect in our study population, the
predictors of both series completion and on-time dosing
should be investigated to further improve proper receipt
of this vaccine.
Despite the promising results presented here, it is
important to note that more than half of girls eligible for
free HPV vaccination in the 2009/10 program year re-
ceived their second dose later than recommended. These
results are not surprising given the H1N1 outbreak and
corresponding immunization campaign that began in the
fall of 2009 that was, understandably, prioritized over
HPV vaccination programs. Another possible explanation
for the delays in receipt may be increased school absentee-
ism due to illness during that time, as was believed to be
the case in Scotland’s school-based program [22]. Regard-
less of the reason, the delays in administration of Dose 2
may have implications in terms of vaccine effectiveness
for the girls affected. Along the same lines, we also found
that a small percentage of girls received doses early. Al-
though there is evidence suggesting that receiving doses
using alternative schedules does not have a major impact
on immunogenicity, [29] the clinical implications of re-
ceiving doses outside of the indicated dosing intervals
should be further investigated.
Although series completion and on-time dosing were
high in this study population, this must be considered in
the context of fairly low HPV vaccine series initiation.
Indeed, only 50% of girls eligible for Ontario’s Grade 8
HPV vaccination program opted to receive the initial
dose of the vaccine, meaning only 42% of all eligible girls
would be regarded as fully immunized. Unfortunately,
despite high HPV vaccine series completion and on-timedosing, such low coverage suggests this vaccination pro-
gram may have a considerably smaller impact on the
burden of disease in the population than anticipated. To
address this issue, Ontario and other programs strug-
gling with low HPV vaccine series initiation should draw
on the strategies implemented by regions that have
demonstrated success, such as Scotland. In particular,
Sinka et al. [22] reported that, following the targeted
efforts made in Scotland to maximize coverage of the
bivalent HPV vaccine [30] more than 90% of all girls
eligible for the country’s publicly funded, school-based
program received the first dose of the vaccine and more
than 80% of eligible girls received all three doses.
A potential limitation of our study is that if a girl moved
to a location outside of the 21 health units for which
immunization data were available her immunization data
may be incomplete. Consequently, our study may have
underestimated series completion. In addition, we did not
have complete follow-up time on girls eligible for the
2009/10 program year since their immunization data were
truncated at March 31 of their Grade 9 year. Nevertheless,
the consistency in series completion across program
years suggests that few girls receive doses after that time.
Another potential source of misclassification is inaccurate
recording of vaccination dates. However, a recent re-
abstraction in one of the health units found that 98.6% of
HPV vaccination dates were accurate in IRIS [13]. Due to
the standardized procedures in place for documenting
immunizations of school-aged children in Ontario, we
expect the high validity of these results to be generalizable
to other IRIS databases. As a result, we expect the impact
of any misclassification of dates to be minimal. A final
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generalizable to areas with different methods of HPV
vaccine program delivery. We would however expect them
to be generalizable to other jurisdictions that provide
the quadrivalent HPV vaccination series to young girls
through free, school-based clinics, such as those that
exist across Canada.
Conclusions
Publicly funded, school-based HPV immunization pro-
grams overcome financial and accessibility barriers to
healthcare, thereby creating an ideal setting in which
vaccine series completion and on-time dosing can be
optimized. Indeed, the results of our study suggest this
approach to program delivery is enabling the vast majority
of girls who initiate the series to complete it according to
the recommended schedule. Nevertheless, our findings
also indicate that removing financial and accessibility bar-
riers alone may not be sufficient for ensuring high HPV
vaccine coverage. Future studies should identify other bar-
riers to HPV vaccine series initiation and investigate the
efficacy and safety of the HPV vaccine when received out-
side of the recommended dosing scheduling.
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